Latest Conference Articles

October 31st 2014, 4:50pm

Annual Meeting of the American Thyroid Association

The impact of RAI on long-term outcomes, potential combination strategies, molecular profiling, and novel therapeutics for patients with thyroid cancer were among some of the topics highlighted at the 2014 ATA Annual Meeting.

October 31st 2014, 4:17pm

Annual Meeting of the American Thyroid Association

Naifa L. Busaidy, MD, associate professor, MD Anderson Cancer Center, discusses the results of a cooperative study that investigated the association between long-term thyroid hormone suppression therapy and improved outcomes in patients.

October 31st 2014, 12:26pm

Chicago Multidisciplinary Symposium in Thoracic Oncology

The PD-1 immune checkpoint inhibitor nivolumab achieved an ORR of 15% with a median duration of response that was not yet reached at a median 11-month follow-up for patients with advanced, refractory NSCLC.

October 31st 2014, 11:41am

Annual Meeting of the American Thyroid Association

Long-term moderate thyroid hormone suppression therapy is associated with improved outcomes in patients with differentiated thyroid cancer.

October 31st 2014, 11:23am

Annual Meeting of the American Thyroid Association

Carmelo Nucera, MD, PhD, endocrinologist, assistant professor, Harvard Medical School, Division of Experimental Pathology, Beth Israel Deaconesss Medical Center, Boston, discusses the role of RNA in thyroid cancer

October 31st 2014, 10:32am

Annual Meeting of the American Thyroid Association

Numerous disease-related variables could serve as prognostic and predictive factors for treatment outcomes with sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer.

October 31st 2014, 8:14am

Chicago Multidisciplinary Symposium in Thoracic Oncology

First-line afatinib (Gilotrif) improved overall survival (OS) by about 1 year in patients with advanced non–small cell lung cancer (NSCLC) whose tumors harbor EGFR exon 19 deletions according to results from the LUX-Lung 3 and the LUX-Lung 6 phase III randomized trials.

October 31st 2014, 8:10am

Annual Meeting of the American Thyroid Association

Ramona Dadu, MD, from the MD Anderson Cancer Center, discusses the results of a pilot study that examined the efficacy of CASAD, a natural clay, to reduce medullary thyroid cancer-related diarrhea.

October 31st 2014, 6:42am

Chicago Multidisciplinary Symposium in Thoracic Oncology

Ramaswamy Govindan, MD, Director, Thoracic Oncology, Co-Director, Section of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the potential for the ALK inhibitor alectinib.

October 31st 2014, 6:32am

Annual Meeting of the American Thyroid Association

Treatment with PD-1 immunotherapy across various oncology clinical trials has been associated with the induction of painless thyroiditis, characterized by transient thyrotoxicosis and hypothyroidism, in patients with metastatic malignancies

October 31st 2014, 6:32am

Chicago Multidisciplinary Symposium in Thoracic Oncology

Patients with NSCLC who received postoperative radiation therapy lived 4 months longer on average than patients who did not receive radiation but who had the same disease site, tumor histology, and treatment criteria, according to a large retrospective study.

October 31st 2014, 5:01am

Chicago Multidisciplinary Symposium in Thoracic Oncology

D. Ross Camidge, MD, PhD, discusses CO-1686 (rociletinib) and AZD9291, two agents that inhibit initial activating EGFR mutations and the T790M resistance mutation.

October 30th 2014, 2:53pm

Annual Meeting of the American Thyroid Association

Ezra Cohen, MD, professor of medicine, UC San Diego Moores Cancer Center, discusses the challenges of treating Medullary Thyroid Cancer (MTC).

October 30th 2014, 2:30pm

Chicago Multidisciplinary Symposium in Thoracic Oncology

Molecular profiling has revealed several tumor markers that could be utilized as therapeutic targets for patients with small cell lung cancer (SCLC) or lung neuroendocrine tumors (NETs).

October 30th 2014, 1:31pm

Chicago Multidisciplinary Symposium in Thoracic Oncology

A new study suggests a knowledge gap in Primary Care Providers' familiarity with screening guidelines could also be a barrier to successful implementation.

October 30th 2014, 12:06pm

Chicago Multidisciplinary Symposium in Thoracic Oncology

Lecia V. Sequist, MD, medical oncologist, associate professor, Massachusetts General Hospital, Harvard Medical School, discusses the overall survival analysis of the LUX-Lung 3 and LUX-Lung 6 trials.

October 30th 2014, 11:11am

Chicago Multidisciplinary Symposium in Thoracic Oncology

Biopsies were found to be the most costly tool used in lung cancer diagnosis, and may be performed too frequently based on negative test results and adverse events.

October 30th 2014, 11:07am

Chicago Multidisciplinary Symposium in Thoracic Oncology

David R. Gandara, MD, from UC Davis Comprehensive Cancer Center, discusses the future of clinical trial designs.

October 30th 2014, 8:06am

Annual Meeting of the American Thyroid Association

New data being presented at the 84th Annual Meeting of the American Thyroid Association show promise for two molecular tests that help identify indeterminate thyroid nodules as either benign or malignant.

October 13th 2014, 8:56am

NANETS Symposium

David C. Metz, MBBCh, professor of medicine, co-director, GI Physiology laboratory, Hospital of the University of Pennsylvania, discusses using a multidisciplinary approach to treating neuroendocrine tumors (NETs).